RNA interference: From gene silencing to gene-specific therapeutics
Open accessThe DOI matches its Crossref record; 211 of the 211 references it cites were found in a registry or an index.
Abstract
In the past 4 years, RNA interference (RNAi) has become widely used as an experimental tool to analyse the function of mammalian genes, both in vitro and in vivo. By harnessing an evolutionary conserved endogenous biological pathway, first identified in plants and lower organisms, double-stranded RNA (dsRNA) reagents are used to bind to and promote the degradation of target RNAs, resulting in knockdown of the expression of specific genes. RNAi can be induced in mammalian cells by the introduction of synthetic double-stranded small interfering RNAs (siRNAs) 21–23 base pairs (bp) in length or by plasmid and viral vector systems that express double-stranded short hairpin RNAs (shRNAs) that are subsequently processed to siRNAs by the cellular machinery. RNAi has been widely used in mammalian cells to define the functional roles of individual genes, particularly in disease. In addition, siRNA and shRNA libraries have been developed to allow the systematic analysis of genes required for disease processes such as cancer using high throughput RNAi screens. RNAi has been used for the knockdown of gene expression in experimental animals, with the development of shRNA systems that allow tissue-specific and inducible knockdown of genes promising to provide a quicker and cheaper way to generate transgenic animals than conventional approaches. Finally, because of the ability of RNAi to silence disease-associated genes in tissue culture and animal models, the development of RNAi-based reagents for clinical applications is gathering pace, as technological enhancements that improve siRNA stability and delivery in vivo, while minimising off-target and nonspecific effects, are developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Silencing SARS‐CoV Spike protein expression in cultured cells by RNA interference
Zhang, Y., Li, T., Fu, L. L., Yu, C., Li, Y., Xu, X., Wang, Y., Ning, H., Zhang, S., Chen, W., et al. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00087-0 · Cited by 149
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · cited 2×
“…was first observed by plant biologists in the late 1980s, but its molecular mechanism remained unclear until the late 1990s, when elegant work in the nematode Caenorhabditis elegans showed that RNAi is an evolu- tionary conserved gene-silencing mechanism (Fire et al., 1998; Reinhart et al., 2000).”
BackgroundDuplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
The nuclear RNase III Drosha initiates microRNA processing
Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Rådmark, O., Kim, S., et al. (2003) · Nature · doi:10.1038/nature01957 · Cited by 5,114
The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans
Reinhart, B. J., Slack, F. J., Basson, M., Pasquinelli, A. E., Bettinger, J. C., Rougvie, A. E., Horvitz, H. R., & Ruvkun, G. (2000) · Nature · doi:10.1038/35002607 · Cited by 4,981
Role for a bidentate ribonuclease in the initiation step of RNA interference
Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 4,892
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“The identification of most of the genes in the human genome has spawned varying estimates of the number of potential new drug targets that await discovery (Drews, 2000; Hopkins & Groom, 2002).”
BackgroundA novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,165
Cited by
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Jackson, A. L., & Linsley, P. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,083
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
siRNA delivery systems for cancer treatment
Oh, Y.-K., & Park, T. G. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.018 · Cited by 645
Inorganic Nanoparticles as Carriers of Nucleic Acids into Cells
Sokolova, V., & Epple, M. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200703039 · Cited by 581
Molecular Mechanisms and Biological Functions of siRNA
Department of Biology, D. B., Dana, H., Chalbatani, G. M., Mahmoodzadeh, H., Gharagouzlo, E., Cancer Research Center, C. I. O. I., Karimloo, R., Department of Medicine, Z. M. S., Rezaiean, O., Moradzadeh, A., et al. (2017) · International Journal of Biomedical Science · doi:10.59566/ijbs.2017.13048 · Cited by 505
Bhaskar, S., Tian, F., Stoeger, T., Kreyling, W., de la Fuente, J. M., Grazú, V., Borm, P., Estrada, G., Ntziachristos, V., & Razansky, D. (2010) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-7-3 · Cited by 495
Nonviral delivery of synthetic siRNAs in vivo
Akhtar, S., & Benter, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33494 · Cited by 464
Cu(0)-Mediated Living Radical Polymerization: A Versatile Tool for Materials Synthesis
Anastasaki, A., Nikolaou, V., Nurumbetov, G., Wilson, P., Kempe, K., Quinn, J. F., Davis, T. P., Whittaker, M. R., & Haddleton, D. M. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00191 · Cited by 436
Improved targeting of miRNA with antisense oligonucleotides
Davis, S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl183 · Cited by 422
Cationic lipids and polymers mediated vectors for delivery of siRNA
Zhang, S., Zhao, B., Jiang, H., Wang, B., & Ma, B. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.07.016 · Cited by 421
Applications of nanoparticles in ophthalmology
Diebold, Y., & Calonge, M. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.08.002 · Cited by 392
Prospects of RNA interference therapy for cancer
Pai, S. I., Lin, Y.-Y., Macaes, B., Meneshian, A., Hung, C.-F., & Wu, T.-C. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302694 · Cited by 352
The canonical Wnt signalling pathway and its APC partner in colon cancer development
Schneikert, J., & Behrens, J. (2007) · Gut · doi:10.1136/gut.2006.093310 · Cited by 290
Role of transforming growth factor-β in hematologic malignancies
Dong, M., & Blobe, G. C. (2006) · Blood · doi:10.1182/blood-2005-10-4169 · Cited by 260
MMP9: A Tough Target for Targeted Therapy for Cancer
Augoff, K., Hryniewicz-Jankowska, A., Tabola, R., & Stach, K. (2022) · Cancers · doi:10.3390/cancers14071847 · Cited by 255
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems
Reischl, D., & Zimmer, A. (2009) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2008.06.001 · Cited by 253
van der Staay, F. J. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.01.006 · Cited by 252
Nonviral methods for siRNA delivery
Gao, K., & Huang, L. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800134q · Cited by 244
Multi-functionalized carbon dots as theranostic nanoagent for gene delivery in lung cancer therapy
Wu, Y.-F., Wu, H.-C., Kuan, C.-H., Lin, C.-J., Wang, L.-W., Chang, C.-W., & Wang, T.-W. (2016) · Scientific Reports · doi:10.1038/srep21170 · Cited by 208
Lönnberg, H. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800406a · Cited by 187
An influenza virus-inspired polymer system for the timed release of siRNA
Truong, N. P., Gu, W., Prasadam, I., Jia, Z., Crawford, R., Xiao, Y., & Monteiro, M. J. (2013) · Nature Communications · doi:10.1038/ncomms2905 · Cited by 181
Ayat, N. R., Sun, Z., Sun, D., Yin, M., Hall, R. C., Vaidya, A. M., Liu, X., Schilb, A. L., Scheidt, J. H., & Lu, Z.-R. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0784 · Cited by 33
“Cationic lipid siRNA nanoparticles have emerged as an advantageous siRNA delivery system due to their simplicity and ability to mediate safe and efficient siRNA delivery [12].”
BackgroundHigh-throughput transfection of interfering RNA into a 3D cell-culture chip
Zhang, H., Lee, M., Hogg, M. G., Dordick, J. S., & Sharfstein, S. T. (2012) · Small · doi:10.1002/smll.201102205 · Cited by 16
Metadata
- Authors
- Leung, R. K. M., & Whittaker, P. A.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2005-08
- Volume
- 107
- Issue
- 2
- Pages
- 222-239
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2110538950
- Cited by
- 382
- References
- 211
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.